Zacks Small-Cap Research

October 26, 2015
Nisha Hirani, MD
312-265-9442 / nhirani@zacks.com
David Bautz, PhD
312-265-9471 / dbautz@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606

AntriaBio, Inc. (ANTB-OTC)

Update

ANTB: Announces Addition of AB301 to the Pipeline…

AntriaBio, Inc. (OTCQB:ANTB) recently announced the addition of AB301 to its product pipeline. AB301 is a weekly injectable combination of a PEGylated human glucagon-like peptide-1 (GLP-1) agonist and AB101, AntriaBio's lead basal insulin product candidate for the potential treatment of type 2 diabetes. Preclinical studies are ongoing and we look forward to learning more about this new product candidate.

Due to the FDA requesting 6 months vs. 1 month of stability data for AB101's drug substance (peginsulin), AntriaBio has adjusted the timeline for the U.S. IND filing to occur by the first half of 2016. We believe AntriaBio remains focused on getting the FDA what it has requested, and we continue to see the current valuation fair at $2.25 per share and maintain our 'Hold' rating.

Current Recommendation	**Hold**
Prior Recommendation	N/A
Date of Last Change	10/07/2014
Current Price (10/26/15)	$1.18
Target Price	**$2.25**

SUMMARY DATA

52-Week High	**$2.25**
52-Week Low	**$0.90**
One-Year Return (%)	**-9.23**
Beta	**-0.87**
Average Daily Volume (sh)	**6,252**
Shares Outstanding (mil)	**24**
Market Capitalization ($mil)	**$29**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**0**
Insider Ownership (%)	**35**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2015 Estimate	**N/A**
P/E using 2016 Estimate	**N/A**

Risk Level	**Above Average**
Type of Stock	**Small-Growth**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue

(In millions of $)

	Q1 (Sep)	Q2 (Dec)	Q3 (Mar)	Q4 (Jun)	Year (Jun)
2014	0 A	0 A	0 A	0 A	0 A
2015	0 A	0 A	0 A	0 A	0 A
2016	0 E	0 E	0 E	0 E	0 E
2017					0 E

Earnings per Share

(EPS is operating earnings before non-recurring items)


	Q1 (Sep)	Q2 (Dec)	Q3 (Mar)	Q4 (Jun)	Year (Jun)
2014	-$0.12 A	-$0.27 A	-$0.76 A	-$0.11 A	-$1.04 A
2015	-$0.12 A	-$0.16 A	-$0.14 A	-$0.13 A	-$0.54 A
2016	-$0.14 E	-$0.10 E	-$0.09 E	-$0.09 E	-$0.40 E
2017					-$0.42 E

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW


Business Update

AntriaBio, Inc. (OTCQB:ANTB) management recently adjusted the timeline for the AB101 U.S. IND filing and clinical trial initiation due to the FDA requiring an additional 5 months of stability data. We now expect that AntriaBio will file the U.S. IND by the first half of 2016, and that the Phase 1 clinical trial should commence during the second half of 2016. AntriaBio also recently added a once-weekly injectable GLP-1 agonist/basal insulin product for type 2 diabetes to its pipeline (AB301), and we will provide more details regarding this candidate below. We will also provide a quick review of the AntriaBio story and conclude with some thoughts on valuation, and long-term potential for investors.



The Path Forward for AB101

AntriaBio has now completed all preclinical pharmacology and toxicology studies in dogs and rats, as well as the build-out of the manufacturing facility in Louisville, CO and plans to produce AB101 material in accordance with current good manufacturing practices (cGMP). AntriaBio is in the process of getting the appropriate certifications for the facility, and we believe that facility will begin to produce fresh cGMP clinical material by the end of calendar year 2015 in preparation for the upcoming Phase 1 trial set to start during the second half of 2016.



AntriaBio has a near-term AB101 clinical development plan in place, and it consists of:

Step 1. File U.S. IND

Management has adjusted the timeline for filing the IND application to the first half of 2016. We were hoping to see the IND filed prior to the end of the fourth quarter of calendar year 2015, but we have learned that AntriaBio was in contact with the FDA through a pre-IND meeting request in order to gain guidance regarding its preclinical and clinical trials for AB101, and that the timeline has been slightly adjusted. Management initially believed that the FDA would require one month of stability data for AB101's drug substance (peginsulin) for the filing of the IND, however

the FDA came back stating that it would like at least six months of stability data. Management is working with the appropriate regulatory consultants, and does not believe that there will be any issues providing or regarding the stability data. This additional data requirement will result in a delay in the IND filing and initiation of the Phase 1 trial and subsequent trials. We hope that AntriaBio will be able to file the IND by the end of the first half of 2016 with no other hurdles so that clinical work can commence. We believe that AntriaBio remains focused on getting the IND filed in a timely fashion once the stability data is collected.

AntriaBio believes that AB101 will likely qualify as a new molecular entity (NME) for listing in the U.S. FDA's Orange Book. However, because the company plans to reference significant historical information on insulin, PEGylation, dissolution, and emulsification, management believes the regulatory hurdle may be more favorable, including the low likelihood the company would have to conduct a dedicated cardiovascular (CV) outcomes study to gain approval or marketing rights. With the FDA requesting more stability data before filing the IND application for AB101, we are not sure if there will be more hurdles down the road. We will have to wait and see. AntriaBio believes the AB101 intellectual property will be protected by existing patents around the PEG attachment to insulin and the mixture of the PEG-insulin with PLGA that do not expire until 2024. New patents have been filed around the manufacturing process that would likely protect AB101 until 2034-2035 based on priority date.

Step 2. Initiate Phase 1 Clinical Study in the U.S.

The objectives of the first clinical study will be to assess the single dose of AB101 in type 1 and type 2 diabetes patients currently using Sanofi's Lantus (insulin glargine). The Phase 1 study will be a single-center, randomized, open label, single ascending dose trial. This will be an in-hospital stay where roughly 40-50 patients will come in stable on Lantus and transitioned to receive one dose of AB101 and then monitored continuously for the next week. The euglycemic clamp technique will be performed on dosing day and at selected time points throughout the anticipated duration of action and is a way to quantify insulin sensitivity. The goal of the study is to demonstrate absence of peak and sustained duration of insulin levels. We believe results will be pretty cut-and-dry with respect to the utility of AB101. If a patient can effectively transition from daily Lantus to once-weekly AB101 with no issues over the following week in terms of glucose control and safety/tolerability, AntriaBio has a blockbuster on its hands. If there are significant issues in terms of patients experiencing hypo- or hyperglycemia or severe adverse events, then AntriaBio needs to go back to the drawing board with respect to the formulation of AB101.

Management was hoping for the first study for AB101 to commence in the fourth quarter of 2015, but with the FDA now requiring six months of stability data prior to the IND filing, this will delay initiation of the AB101 clinical program. According to the new timeline, management now believes that the study should begin at some point during the second half of 2016. We will have a better sense of the exact timing of this first study once the IND has been filed. With the adjusted timeline, we now believe data from the first clinical study can be generated by the end of 2016. We believe this study will cost an estimated $4-5 million all-in for AntriaBio.

Step 3. Move into Phase 2 Clinical Studies in the U.S.

Following successful completion of the Phase 1 clinical studies noted above, Phase 2 trials should begin in both type 1 and type 2 diabetics. These will primarily be longer-duration safety and tolerability studies, with accepted biomarkers for glucose efficacy (i.e. HbA1c) comparing AB101 to a standard of care basal insulin such as Sanofi's Lantus. If the proof-of-concept trials are successful, we expect the company to expand the clinical program to include Phase 3 registration trials in various regions around the world, including the U.S. and Europe.

Ultimately, if all goes well and the data are positive, we expect AntriaBio to look to partner AB101 with a larger pharmaceutical company with a heavy presence in the diabetes market, such as Novo Nordisk, Sanofi, and Eli Lilly. Other major players include Merck, Bristol-Myers, Roche, Novartis, Boehringer Ingelheim, and AstraZeneca. However, to get to the point where partnering AB101 is feasible, we believe the company will need to complete through Phase 2 clinical testing in the U.S. The goal is to show endpoints of glycemic control and safety comparable to a product like Lantus. Management believes there may also be an earlier opportunity to evaluate whether a partnership would make sense after the data readout from the Phase 1 clinical trial (in advance of completion of Phase 2 testing).


AB301: New Product Enters the Pipeline

On September 16, 2015, AntriaBio announced the addition of a new product candidate to its pipeline. AB301 is a weekly injectable combination of a PEGylated human glucagon-like peptide-1 (GLP-1) agonist and AB101, AntriaBio's basal insulin lead product candidate for the potential treatment for patients with type 2 diabetes. As per

management, *in vitro* and *in vivo* studies that have been completed to date show that AB301 has the potential to be a well-tolerated, effective therapy for type 2 diabetes. Currently, AntriaBio is working on additional ongoing preclinical studies of AB301, and believes that a combination therapy has the potential to complement glycemic control while attenuating weight gain and hypoglycemic risk. Although it is still early on in the process, we will have a better sense of the potential when preclinical data and additional details become available.

GLP-1 agonists are now well-established treatment options for type 2 diabetes, and so we view this as good news for AntriaBio. There are numerous marketed daily and weekly GLP-1 agonists, and so AB301 hopes to differentiate itself by offering a combination therapy with extended duration of action. GLP-1 agonists work by stimulating the pancreas to produce and secrete insulin in response to eating meals. The benefit of this type of state-dependent stimulation is that once the blood sugar levels decrease to normal, the pancreatic response to produce insulin is reduced, unlike exogenously delivered insulin which can be over-dosed and creates the risk of hypoglycemia. GLP-1 agonists also work by suppressing the pancreatic release of glucagon in response to eating, which helps stop the liver from over-producing unneeded sugar. This helps to reduce the risk of hyperglycemia.

Amylin/Astrazeneca's Bydureon (exenatide), a currently marketed GLP-1 agonist for type 2 diabetes, is also formulated using PLGA microspheres (*below*). We have discussed Bydureon in previous updates, but as a quick recap, it is a long-acting form of the medication Byetta. Bydureon had worldwide sales of $440 million in 2014, and is projected to have over $1 billion in peak sales.



We would also like to point out that there are currently some big players in the GLP-1 agonist/basal insulin combination therapy space but they are targeting once-daily dosing, as opposed to AntriaBio's AB301 which is proposed to be a weekly injectable. Novo Nordisk's Xultophy (IDegLira) is a fixed-dose once-daily combination of Tresiba (insulin degludec) and Victoza (liraglutide), and recently completed Phase 3 development in the U.S. and was approved in all 28 EU member states and Switzerland in September 2014. Novo Nordisk submitted the NDA for Xultophy to the FDA in September 2015. As way of background, Tresiba, the basil insulin component of Xultophy, was not approved by the FDA in 2013 due to concerns related to cardiovascular risk. Xultophy could not be submitted to the FDA until Tresiba received FDA approval, which finally occurred on September 25, 2015. We are not exactly sure when Xultophy will be approved in the U.S., but want to reiterate that it is a once-daily combination therapy.

Sanofi's LixiLan is a fixed-ratio once-daily combination of Lantus (insulin glargine) and Lyxumia (lixisenatide) that is currently in Phase 3 development in the U.S. Sanofi reported positive Phase 3 top-line results Phase 3 with LixiLan meeting the primary endpoint of showing superior reduction in HbA1c vs. insulin glargine. We believe regulatory submissions are planned for the fourth quarter 2015 in the United States and the first quarter 2016 in the EU. Once again, LixiLan is proposed to be a once-daily dosing for type 2 diabetes.


We believe that pursuing this combination therapy was the next logical step for AntriaBio, given the success with GLP-1 agonists, and some larger names moving forward with GLP-1 agonists/basil insulin combination therapies. We think the combination of a GLP-1 agonist with basal insulin on a weekly dosing regimen makes a lot of sense as we continue to believe that there is a need for effective sustained release drug delivery systems that would minimize dosing frequency, improve patient compliance and therapeutic effectiveness, as well as potentially reduce costs. Although it is still early on in the process, we believe that AntriaBio plans to continue with preclinical studies and plans to submit an abstract by the end of calendar year 2015 to the ADA, in hopes to present AB301 data at the American Diabetes Association 76th Scientific Sessions® in June 2016. We are looking forward to reviewing the data once it is available.

Quick Review of AB101


AntriaBio is developing AB101, a product that aims to be the first once-weekly basal insulin. AB101 is a formulation of human recombinant insulin (non-analog) for subcutaneous injection that is designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst. AB101 is a proprietary formulation developed by the company to preserve the integrity and biological activity of insulin through the manufacturing process. Despite the once-weekly dosing regimen, the dose of AB101 can be administered in an acceptable volume through a relatively small (narrow gauge) needle. AB101 was engineered to provide desired release kinetics using a common biodegradable material called PLGA or poly(lactic-co-glycolic acid). PLGA biodegrades through a very predictable and consistent hydrolysis, eliminating an initial undesirable burst of insulin release. With these characteristics, AB101 should provide high quality basal insulin for the majority of insulin-dependent diabetics without significant injection site reaction or burst of serum insulin levels.

- ***How Is AB101 Made?***

AntriaBio is not the first company to attempt to develop a once-weekly basal insulin injection. Many have failed in formulation work prior to AntriaBio's AB101. There are essentially two strategies to develop a weekly basal insulin injection, either formulate with polyethylene glycol (PEG) or encapsulate in PLGA or polyglutamate (pGlu) microspheres.




Step-1: PEGylation: Formulation with PEG has been a well-documented strategy for improving half-life and extending duration of action. PEGylation is known to enhance protein stability and solubility, reducing dosing frequency, and enhancing plasma circulation. Numerous pharmaceutical products have been attached to PEG, including granulocyte colony-stimulating factor (Amgen's Neulasta), certolizumab (UCB's Cimzia), anti-VEGF aptamer (Pfizer's Macugen), alpha-interferon (Merck's PEGintron, Roche's Pegasys), adenosine deaminase (Enzon's Adagen), and uricase (Savient's Pegloticase), to name a few.




Step-2: Dissolution: Dissolving PEG-insulin with a polymer such as PLGA is a strategy designed to facilitate delivery of dose and allow extended release of the PEG-insulin into the body by hydrolysis. Dissolution of PLGA

allows a slow release of the PEG-insulin at a controlled rate designed by AntriaBio scientists based on the monomers used in the formulation.



Step-3: Emulsion: After the PEG-Insulin and PLGA are dissolved in a solvent, the mixture is put through an emulsification process to create uniform, monolithic microspheres. An oil-in-water emulsion is generated by passing both the oil and water phases through a packed glass bead bed emulsifier. After the solution is delivered, the microspheres are degraded by hydrolysis at a uniform and controlled rate, releasing the PEG-insulin into circulation.



AB101 Preclinical Studies

As a reminder, AntriaBio announced preclinical results for its once-weekly basal insulin candidate, AB101, in a presentation titled "*The in Vitro and in Vivo Pharmacology of AB101, a Potential Once-Weekly Basal Subcutaneous Insulin*" at the American Diabetes Association 75th Scientific Sessions® in June 2015. The data support our belief that AB101 will be the first once-weekly basal insulin product. We discussed the data in depth in our previous update. The results from the preclinical proof of concept pharmacology studies showed that AB101 has comparable *in vitro* pharmacology to native insulin, and in two animal species (rats and dogs) displayed an extended subcutaneous insulin absorption profile, leading to slow onset, peakless and sustained insulin levels with corresponding reductions in glucose levels, without acute hypoglycemia caused by an initial insulin burst. As per management, these observations occurred at clinically relevant dose projections, demonstrating proof of concept of the potential for AB101 as a weekly subcutaneous basal insulin therapy in patients with diabetes mellitus. We view these results as encouraging, with no initial undesirable effects of insulin bursts or hypoglycemia seen in the animal models. We believe the preclinical data supports moving forward with AB101.

Financial Update

On September 28, 2015, AntriaBio, Inc. filed its Form 10-K reporting financial results for the fiscal year ended June 30, 2015. As expected, AntriaBio did not generate any revenues as it is a preclinical stage company. Net loss for the fiscal year ended June 30, 2015 was $11.4 million, or $0.54 per share, was $1.5 million narrower than our expectations. Research and development costs were approximately $1.3 million in the 2015 quarter compared to $30k in the same quarter in 2014, and the increase is due to the company starting significant R&D activities during the 2015 period. General and administrative costs were approximately $1.4 million in the 2015 quarter compared to $2.2 million in the 2014 quarter.

As of June 30, 2015, the company held $5.7 million in cash and cash equivalents. AntriaBio burned $4.2 million in cash from operations and investments for the three-month period ending June 30, 2015. Burn for the previous quarter ending March 31, 2015 was approximately $2.9 million. We had anticipated that the burn rate would increase quarter-over-quarter, and we continue to believe the burn rate will rise over the next few quarters as the company prepares for IND filing for AB101 as well as the clinical trial programs for AB101 and newly announced pipeline candidate AB301, and manufacturing materials at the newly completed cGMP facility. We believe AntriaBio will need to raise more cash in the very near term as they will likely burn through most of their cash balance early in its fiscal second quarter 2016. We believe that in order to accomplish the primary objective of conducting its first clinical study for AB101, which is now anticipated to begin during the second half of 2016 as per the recently adjusted timeline, the company will require additional funding. We expect this study to cost approximately $4-5 million, and believe AntriaBio will require an additional $15-20 million in capital to get them through the end of calendar year 2016. We believe that AntriaBio is actively pursuing financing options at this point.

As a reminder, AntriaBio raised approximately $22 million in the calendar year 2014 and first calendar quarter of 2015. The company goal was to raise $25-30 million in order to obtain near term objective of generating human proof of concept data for AB101. Late in December 2014, AntriaBio raised approximately $6.2 million in cash (net) through a private placement transaction by issuing approximately 3.8 million units at $1.85 per share. Units consisted of one share of common stock and one warrant to purchase a new share of stock exercisable at $2.50 per share over the next three years.

Conclusion

Diabetes is a major public health challenge. According to the American Diabetes Association, 29.1 million Americans, or 9.3% of the population, had diabetes in 2012. In 2012, 86 million Americans over the age of 20 had pre-diabetes, which is up from 79 million in 2010. The International Diabetes Federation estimates that there are 387 million individuals worldwide with diabetes, and this number is projected to grow to over 470 million by 2035.

We believe there is a need for novel, and safe therapeutics that allow for proper glucose control, less frequent dosing in addition to slow and uniform insulin release without an adverse initial burst. We believe that if the clinical data for AB101 resembles the preclinical data and are positive, AntriaBio could have a blockbuster product on its hands. If there are any issues with hypo- or hyperglycemia or severe adverse events, then AntriaBio will need look at reformulation of AB101.

With the recent news of the FDA requiring six months of stability data, we view the delay in filing the IND for AB101 to be unfortunate, however we do believe that AntriaBio remains focused and on track to get this done by the end of the first half of 2016. We are not sure if the FDA will have any other regulatory requirements down the road, but if there are any, there may be additional delays to the timeline. We would like to remind investors of what happened with Bydureon, as it was initially met with resistance by the U.S. FDA. With respect to Bydureon, Amylin took three attempts to gain approval for the drug. The NDA was filed in May 2009. In March 2010 the FDA responded with a complete response letter (CRL) noting deficiencies around the manufacturing process and product labeling. The FDA also asked for additional information around the Risk Evaluation and Mitigation Strategy (REMS). Amylin responded with a second NDA in April 2010. This was met with a second complete response letter in October 2010. This time the FDA asked for information around the cardiovascular safety of Bydureon. Amylin conducted a thorough QT study to show no effect on QT prolongation, an important predictor of certain heart arrhythmias. The application was re-filed in July 2011, and finally approved in January 2012. We highlight the Amylin/Bydureon story because we believe that path forward for AB101 may not be as straightforward for as AntriaBio had hoped, and there may be several other hiccups along the way that could further derail the timeframe. That being said, we continue to view AB101 as a promising new insulin option for individuals with diabetes.

We also believe that AntriaBio will need to raise an additional $15-20 million to get through calendar year 2016. We have seen the company raise over $20 million in 2014/early 2015, and we are hopeful that they will be able to do it again in order to continue with development for AB101 and AB301. However, we are unsure if AntriaBio will be able to do it in a timely fashion in order to adhere to the newly adjusted timeline. We will have a better sense of the path forward once the IND is filed and the clinical program for AB101 has commenced. Other upcoming milestones that the company is focused on achieving include preparing for the initiation of AB101 Phase 1 first-in-human clinical study, and the continuation of preclinical studies for new product candidate AB301.

Upon reviewing the preclinical proof of concept pharmacology data for June 2015, we continue to remain optimistic regarding the AB101 story. In our opinion, it was very reassuring to see that no acute undesirable insulin bursts or

glucose reductions were observed. Furthermore, we believe that the slow onset, sustained insulin increases with corresponding glucose reductions over the course of about one week in both the dog and rat species support a once-weekly dosing of basal insulin for patients with diabetes. Obviously, it is still early on in the process, but we view these results as encouraging. We are hopeful that the efficacious doses used in the animal models will be readily translated to human clinically relevant doses and dose volumes. Management believes that the inter-species homology of insulin/receptor predicts insulin activity in humans, and we are hoping, that in the future, results from human trials show this predictable pattern. At this point, we continue to view AB101 as a promising new insulin therapy option for individuals with diabetes as well as clinicians. The preclinical data shows that the once-weekly injection offers a reproducible, slow and sustained release of insulin and reduction in glucose over the intended weekly dosing period, which if translated to patients with diabetes should provide uniform glycemic control with the convenience and compliance of a once-weekly injection and a lower risk of hyperglycemia.

We also believe that AntriaBio's new pipeline candidate, AB301, could have potential if all goes well with AB101 and if the data is positive. It is still early for us, but as mentioned above, we believe that the combination of a GLP-1 agonist with basal insulin on a weekly dosing regimen makes a lot of sense as there is a need for effective sustained release drug delivery systems that would minimize dosing frequency, improve patient compliance and therapeutic effectiveness. AntriaBio's product is proposed to be a once weekly candidate, while other big pharmaceutical companies are developing daily candidates.

We believe AB101 has peak sales in the area of $3.5 billion by 2028 if the clinical data are positive. We believe there are a number of value-creating inflection points on the horizon over the next several years, culminating with the signing of a major development and commercialization partnership for AB101 after the Phase 1/2 data has been generated. As noted above, we expect the results of the Phase 1 proof-of-concept study to be pretty straightforward and hope to see the data by the end of 2016. We will be able to see the insulin profile, and either AB101 works or it does not. If it works, we believe that AB101 could see a ten-fold increase in valuation as big pharmaceutical companies like Sanofi, Novo Nordisk and Eli Lilly, now become interested in acquiring the company.

Based on historical "big pharma / small-biotech" take-outs, we believe a deal will get done prior to the initiation of the pivotal registration program if the Phase 1/2 data are positive. We believe a company like Sanofi or Eli Lilly would be quite comfortable paying a premium to acquire AB101 if their internal numbers agree with our modeling that peak sales are in the $3.5 billion range by 2028.

We have built a financial model forecasting the risk-adjusted potential cash flow from selling AB101 on a global basis. Our assumptions include filing the U.S. NDA in 2020 and launching the product in 2021. We model peak sales of $3.5 billion in 2028 with 70% net operating margin at peak. We assuming exclusivity at 100% until 2024 and then risk-adjust the cash flow from 2025 to 2035 down by 50% until the new patents around the manufacturing process have been granted. At this stage, we are still assuming 10% probability of success. Positive AB101 Phase 1/2 data would provide meaningful upside to the AntriaBio story and increased probability of success. We have not yet factored in AB301 to our model, as it is still early and we believe it is largely dependent on what happens with AB101. We continue to believe the shares are worth approximately $2.25 right now, and maintain our "Hold" rating.


PROJECTED FINANCIALS

AntriaBio, Inc. - Income Statement

AntriaBio, Inc.	Jun. 2015 FY-15 A	Sept. 2015 Q1 E	Dec. 2015 Q2 E	Mar. 2016 Q3 E	Jun. 2016 Q4 E	Jun. 2016 FY-16 E	Jun. 2017 FY-17 E
AB101 Sales / Royalties	$0	$0	$0	$0	$0	$0	$0
YOY Growth	-	-	-	-	-	-	-
Licensing / Collaborative	$0	$0	$0	$0	$0	$0	$0
YOY Growth	-	-	-	-	-	-	-
Total Revenues	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**
YOY Growth	-	-	-	-	-	-	-
CoGS	$0	$0	$0	$0	$0	$0.0	$0.0
Product Gross Margin	-	-	-	-	-	-	-
R&D	$4.7	$1.9	$2.0	$2.1	$2.2	$8.2	$12.2
SG&A + Other	$6.0	$1.6	$1.7	$1.8	$1.9	$7.0	$8.0
Operating Income	**($10.7)**	**($3.5)**	**($3.7)**	**($3.9)**	**($4.1)**	**($15.2)**	**($20.2)**
Operating Margin	-	-	-	-	-	-	-
Interest & Other Income	($0.7)	$0.1	$0.1	$0.1	$0.1	$0.5	$0.5
Pre-Tax Income	($11.4)	($3.4)	($3.6)	($3.8)	($4.0)	($14.7)	($19.7)
Taxes & Other	$0	$0	$0	$0	$0	$0	$0
Tax Rate	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*
Net Income	($11.4)	($3.4)	($3.6)	($3.8)	($4.0)	($14.7)	($19.7)
Net Margin	-	-	-	-	-	-	-
Reported EPS	**($0.54)**	**($0.14)**	**($0.10)**	**($0.09)**	**($0.09)**	**($0.40)**	**($0.42)**
YOY Growth	-	-	-	-	-	-	-
Basic Shares Outstanding	21.0	24.3	36.0	40.0	45.0	36.3	46.5

Source: Company Filing // Zacks Investment Research, Inc. Estimates

HISTORICAL ZACKS RECOMMENDATIONS



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

We, Nisha Hirani, MD, and David Bautz, PhD, hereby certify that the views expressed in this research report accurately reflect our personal views about the subject securities and issuers. We also certify that no part of our compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. We believe the information used for the creation of this report has been obtained from sources we considered to be reliable, but we can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESMENT BANKING, REFERRALS, AND FEES FOR SERVICE

Zacks SCR does not provide nor has received compensation for investment banking services on the securities covered in this report. Zacks SCR does not expect to receive compensation for investment banking services on the Small-Cap Universe. Zacks SCR may seek to provide referrals for a fee to investment banks. Zacks & Co., a separate legal entity from ZIR, is, among others, one of these investment banks. Referrals may include securities and issuers noted in this report. Zacks & Co. may have paid referral fees to Zacks SCR related to some of the securities and issuers noted in this report. From time to time, Zacks SCR pays investment banks, including Zacks & Co., a referral fee for research coverage.

Zacks SCR has received compensation for non-investment banking services on the Small-Cap Universe, and expects to receive additional compensation for non-investment banking services on the Small-Cap Universe, paid by issuers of securities covered by Zacks SCR Analysts. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, equity research, investment management, non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per client basis and are subject to the number of services contracted. Fees typically range between ten thousand and fifty thousand USD per annum.

POLICY DISCLOSURES

Zacks SCR Analysts are restricted from holding or trading securities placed on the ZIR, SCR, or Zacks & Co. restricted list, which may include issuers in the Small-Cap Universe. ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Each Zacks SCR Analyst has full discretion on the rating and price target based on his or her own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for services described above. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but are not guaranteed as to be accurate nor do we purport to be complete. Because of individual objectives, this report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

ZACKS RATING & RECOMMENDATION

ZIR uses the following rating system for the 1206 companies whose securities it covers, including securities covered by Zacks SCR:
Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters.
Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters.
Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution is as follows: Buy/Outperform- 26.5%, Hold/Neutral- 53.7%, Sell/Underperform – 16.3%. Data is as of midnight on the business day immediately prior to this publication.